Vozmozhnosti primeneniya zolendronata v lechenii osteoporoza


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Treatment with bisphosphonates (BP) is a key element for any form of osteoporosis (OP). Zoledronic acid (ZA) takes a special place among the BP; ZA called Aclasta is registered in Russia in late 2006; Aclasta is the first drug for the use once a year in OP. The results of numerous clinical studies supporting the efficacy of ZA in patients with OP are presented. It is emphasized that long-term experience of treatment with ZA in combination with its high efficacy in the prevention of fractures of various localization, and convenient regimen of application lead to the preference of doctors to choose this BP as therapy OP. Timely use of the ZA in the complex antiosteoporotic therapy makes an indispensable contribution to the successful treatment of various forms of OP and contributes to solving the ultimate goal of treatment for the disease - reducing the risk of osteoporotic fractures.

Full Text

Restricted Access

About the authors

E. V Biryukova

Email: lena@obsudim.ru

References

  1. Лесняк О.М. Аудит состояния проблемы остеопороза в странах Восточной Европы и Центральной Азии 2010. Остеопороз и остеопатии. 2011; 2: 3-6.
  2. Риггз Б.Л., Мелтон III Л.Д. Остеопороз. Этиология, диагностика, лечение. М., 2000.
  3. Lips P., Cooper C., Agnusdei D., et al. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos. Int 1999; 10: 150-60.
  4. Riggs B.L., Khosla S., Melton L.J. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 1998; 13: 763-73.
  5. Davidson M.R. Pharmacotherapeutics for osteoporosis prevention and treatment. J. Midwifery Women's Health 2003; 48: 39-52.
  6. Hollevoet N., Verdonk R., Jean-Marck K., Goemaere S. Osteoporotic fracture treatment. Acta Orthop. Belg. 2011; 74(4): 442-47.
  7. Carbonare L.D., Zanatta M., Gasparetto A., Valenti M.T. Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc. Patient Saf. 2010; 2: 121-37.
  8. Painter S.E., Kleerekoper M., Camacho P.M. Secondary osteoporosis: a review of the recent evidence. Endocr. Pract. 2006; 12(4): 436-45.
  9. Woolf A.D. An update on glucocorticoid-induced osteoporosis. Curr. Opin. Rheumatol. 2007; 19: 370-75.
  10. Eastell R. Treatment of postmenopausal osteoporosis. N. Engl. Med. J. 1998; 338(11): 736-46.
  11. van Staa T., Leufkens H.G.M., Cooper C. The epidemiology of corticosteroid-induced osteoporosis. Osteopros. Int 2002; 13: 777-87.
  12. Коршунов Н.И., Ершова О.Б., Белова К.Ю. Глюкокортикоидный остеопороз: диагностика и лечение. РМЖ. 2007; 6: 546-49.
  13. Mauck K.F., Clarke B.L. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin. Proc. 2006; 81(5): 662-72.
  14. Lawrence V.A., Hilsenbeck S.G., Noveck H., et al. Medical complications and outcomes after hip fracture repair. Arch. Intern. Med. 2002; 162: 2053-57.
  15. Bouvard B., Audran M., Legrand E., Chappard D. Ultrastructural characteristics of glucocorticoid-induced osteoporosis. Osteoporos. Int. 2009; 20: 1089-92.
  16. Canalis E., Mazziotti G., Giustina A., Bilezikian J.P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 2007; 18: 1319-28.
  17. Клинические рекомендации. Остеопороз. 2-е издание, переработанное и дополненное под ред. Л.И. Беневоленской, О.М. Лесняк. М., 2009. 269 с.
  18. Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 2008; 83(9): 1032-45.
  19. Nancollas G.H., Tang R., Gulde S., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006; 38(5): 617-27.
  20. Rogers M.J. New insights into molecular mechanisms of action of bisphosphonates. Curr. Pham. Des. 2003; 9: 2643-58.
  21. Russell R.G.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanism of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 2008; 19(6): 733-59.
  22. Vitte C., Fleisch H., Guenther H.L. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast mediated resorption. Endocrinology. 1996; 137(6): 2324-33.
  23. Инструкция по медицинскому применению лекарственного препарата Акласта. Регистрационный номер: ЛС-002514.
  24. Fleish H. Bisphosphonates: Mechanism of action. Endocrine Rev. 1998; 19(1): 80-100.
  25. Kavanagh K.L., Guo K., Dunford J.E., et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc. Natl. Acad. Sci. USA. 2006; 103(20): 7829-34.
  26. Siris S.E., Harris S.T., Rosen C.T., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic. women: relationship to vertebral and nonvertebral fractures from 2 US claims data bases. Mayo Clin. Proc. 2006; 81(8): 1013-22.
  27. Recker R.R., Delmas P.D., Halse J., et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J. Bone Miner. Res. 2008; 23(1): 6-16.
  28. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis: HORIZON Pivotal Fracture Trial. N. Engl. J. Med. 2007; 356(18): 1809-22.
  29. Cauley J.A., Thompson D.E., Ensrud K.C., et al. Risk of mortality following clinical fractures. Osteoporos Int. 2000; 11: 556-61.
  30. Center J.R., Nguyen T.V., Schneider D., et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999; 353: 878-82.
  31. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 2007; 357(18): 1799-809.
  32. Reid D.M., Devogelaer J.P., Saag K., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoprosis (HORIZON): a multicentre, doubleblind, double-dummy, randomised controlled trial. Lancet. 2009: 373: 1253-63.
  33. Serefoglu E.C., Tandogdu Z. Efficacy and safety of zoledronic acid in the treatment of gluco-corticoidinduced osteoporosis. Ther. Clin. Risk Manag. 2010; 6: 219-23.
  34. Boonen S., Reginter J.-Y., Kaufman J.-M., et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N. Engl. J. Med; 367: 1714-23.
  35. Strampel W.I., Emkey R., Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf. 2007; 30(9): 755-63.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies